Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology

Advanced search

Pharmacoeconomic analysis of the use of a fixed combination of tiotropium bromide and olodaterol as maintenance therapy in patients with chronic obstructive pulmonary disease in the Russian Federation

https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.144

Abstract

Objective: to evaluate the pharmacoeconomic effectiveness of the use of a fixed double combination of tiotropium bromide + olodаterol in order to treat chronic obstructive pulmonary disease (COPD) in comparison with less expensive monotherapy with long-acting beta-2-agonists (LABA) or long-acting anticholinergics (LAAC) with its insufficient effectiveness.

Material and methods. The analysis of the impact on the health care system budget of the use of a fixed double chemical combination was carried out. The combination used was the one of tiotropium bromide + olodаterol in patients suffering from COPD who do not achieve effective disease control during LABA or LAAC monotherapy. We used published data on the distribution of patients into groups according to the classification of the Global Initiative for Chronic Obstructive Lung Disease (GOLD), also according to the therapy used and the frequency of exacerbations with hospitalization, obtained in a Russian epidemiological study. Direct and indirect costs associated with basic therapy and treatment of exacerbations requiring hospitalization were estimated as well.

Results. Previously, it was shown that about 21.8% of patients with GOLD D severity of COPD receive therapy of insufficient efficacy (LABA monotherapy or long-acting M-cholinolytics). The use of a fixed combination of tiotropium bromide + olodaterol in such patients instead of monotherapy will reduce the direct costs of hospitalization by 21.1%, and the total costs (direct and indirect) – by 4.6%. On the scale of the Russian Federation, this will save 17.2 billion rubles a year.

Conclusion. The results obtained showed that, despite the reasonably high cost of a fixed double combination in comparison with monopreparations, the use of double bronchodilating therapy allows to achieve more effective treatment and reduces both direct medical costs associated with hospitalization of patients with exacerbations of COPD, and direct non-medical and indirect costs associated with absenteeism of patients to work due to temporary disability as a result of hospitalization.

About the Authors

S. К. Zyryanov
Peoples’ Friendship University of Russia; City Clinical Hospital No. 24
Russian Federation

Sergey К. Zyryanov – Dr. Med. Sc., Professor, Chief of Chair of General and Clinical Pharmacology; Deputy Chief Physician. WoS ResearcherID: D-8826-2012; Scopus Author ID: 35796816700; RSCI SPIN-code: 2725-9981

10 corp. 3 Miklukho-Maklay Str., Moscow 117198
10 Pistsovaya Str., Moscow 127015



I. N. Dyakov
Scientific and Practical Center for Problems of Rational Pharmacotherapy and Pharmacoeconomics; Mechnikov Research Institute of Vaccines and Serums
Russian Federation

Ilya N. Dyakov – PhD (Biol.), Director General; Head of Laboratory of Immunoglobulin Biosynthesis, Leading Researcher. WoS ResearcherID: K-2024-2018; Scopus Author ID: 25723245000; RSCI SPIN-code: 1854-0958

50 bldg 2 Aviamotornaya Str., Moscow 111024
5A Malyy Kazennyy Dr., Moscow 105064



References

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020 Report. Available at: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf (accessed 03.06.2022).

2. Chronic obstructive pulmonary disease. Clinical guidelines. Ministry of Health of the Russian Federation. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/603_2 (accessed 03.06.2022).

3. Lamprecht B., McBurnie M.A., Vollmer W.M., et al. COPD in never smokers: results form the population-based burden of obstructive lung disease study. Chest. 2011; 139 (4): 752–63. https://doi.org/10.1378/chest.10-1253.

4. Chuchalin A.G., Khaltaev N., Antonov N.S., et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014; 9: 963–74. https://doi.org/10.2147/COPD.S67283.

5. Nguyen T. Evidence-informed policy making: bridging the gap. Public Health Panorama. 2016; 2: 257.

6. van der Molen T., Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J. 2012; 21 (1): 101–8. https://doi.org/10.4104/pcrj.2011.00102.

7. Mahler D.A., Decramer M., D’Urzo A., et al. Dual bronchodilatation with QVA149 reduces patient reported dyspnea in COPD: the BLAZE study. Eur Respir J. 2014; 43 (6): 1599–609. https://doi.org/10.1183/09031936.00124013.

8. Arkhipov V., Arkhipova D., Miravitlles M., et al. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial. Int J Chron Obstruct Pulmon Dis. 2017; 12: 3255–62. https://doi.org/10.2147/COPD.S142997.

9. Calverley P.M., Anzueto A.R., Carter K., et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018; 6 (5): 337–44. https://doi.org/10.1016/S2213-2600(18)30102-4.

10. Decramer M.L., Chapman K.R., Dahl R., et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013; 1 (7): 524–33. https://doi.org/10.1016/S2213-2600(13)70158-9.

11. Sethi S., Kerwin E., Watz H., et al. AMPLIFY: a randomized, phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14: 667–82. https://doi.org/10.2147/COPD.S189138.

12. State Register of Marginal Selling Prices. Available at: https://grls.rosminzdrav.ru/pricelims.aspx (in Russ.) (accessed 03.06.2022).

13. Decree of the Government of the Russian Federation of 28.12.2021 No. 2505 “On the Program of state guarantees of free provision of medical care to citizens for 2022 and for the planning period of 2023 and 2024”. Available at: https://base.garant.ru/403335795/ (in Russ.) (accessed 03.06.2022).

14. Order of the Ministry of Health of the Russian Federation of 20.12.2012 No. 1214n “On approval of the standard of primary health care for exacerbation of chronic obstructive pulmonary disease”. Available at: https://minzdrav.gov-murman.ru/documents/poryadki-okazaniya-meditsinskoy-pomoshchi/pr_MZ_RF_1214.pdf (in Russ.) (accessed 03.06.2022).

15. Federal State Statistics Service. Available at: https://rosstat.gov.ru (in Russ.) (accessed 03.06.2022).

16. Karner C., Cates C.J. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011; 3: CD008532. https://doi.org/10.1002/14651858.CD008532.pub2.


Review

For citations:


Zyryanov S.К., Dyakov I.N. Pharmacoeconomic analysis of the use of a fixed combination of tiotropium bromide and olodaterol as maintenance therapy in patients with chronic obstructive pulmonary disease in the Russian Federation. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(2):188-198. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.144

Views: 250


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)